The company's SRS endoscope is a minimally invasive treatment for gastric reflux.
Medigus Ltd. (TASE:MDGS) has received US Food and Drug Administration (FDA) approval for its SRS endoscope for minimally invasive treatment of gastroesophageal reflux disease (GERD), and will launch marketing in the US immediately. The company has already received EU CE Mark certification of the product.
A multicenter clinical trial of the endoscope found it effective and safe.
Medigus cites various studies, which say that GERD affects 5-17% of the world's population, according to various sources, and has a potential market of up to $33 billion in the US.
Medigus's share price rose 5% by mid-afternoon to NIS 1.12, giving a market cap of NIS 90 million.
Published by Globes [online], Israel business news - www.globes-online.com - on May 24, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012